Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Business Segments — R&D

Similar metrics at other companies

Immunovant, Inc. logo
IMVTReportable Segment — R&D
$29.22M-6.2%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — R&D
$16M-27.3%
Neurocrine Biosciences logo
NBIXReportable Segment — R&D
$296.2M+12.5%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — R&D
$57.09M+21.8%
Evolus logo
EOLSReportable Segment — R&D
$1.89M+3.0%
Zymeworks logo
ZYMEReportable Segment — R&D
$27.44M-20.4%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$681.73M+6.6%
Enterprise value$537.9M-17.8%
P/E11.7×-230×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Total revenues$39,663$25,881$75,883$46,282
Less significant segment expenses:
Research and development directly identified to programs2,2062,3395,1384,700
Research and development not directly identified to programs2,2801,0943,7401,991
Selling, general and administrative directly identified to programs3,1326,4399,56414,000
Selling, general and administrative not directly identified to programs13,42714,34327,77826,327
Other segment items:
Impairment of intangible assets58,71058,710

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s business segments — R&D?
Zevra Therapeutics, Inc. (ZVRA) reported business segments — R&D of $2.28M in Q2 2026.
How has Zevra Therapeutics, Inc.'s business segments — R&D changed year-over-year?
Zevra Therapeutics, Inc.'s business segments — R&D decreased by 2.5% year-over-year, from $2.34M to $2.28M.
What does business segments — R&D mean?
Captures the direct costs associated with research and development activities specifically identified to the segment's drug pipeline. Monitoring these expenditures is essential for evaluating the company's commitment to innovation and the progression of its rare disease therapeutic portfolio.

Ask your AI about Zevra Therapeutics, Inc.'s business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude